BeOne Medicines Ltd
265 hedge funds and large institutions have $11.2B invested in BeOne Medicines Ltd in 2025 Q3 according to their latest regulatory filings, with 62 funds opening new positions, 91 increasing their positions, 78 reducing their positions, and 40 closing their positions.
55% more first-time investments, than exits
New positions opened: 62 | Existing positions closed: 40
35% more capital invested
Capital invested by funds: $8.34B → $11.2B (+$2.89B)
17% more repeat investments, than reductions
Existing positions increased: 91 | Existing positions reduced: 78
9% more funds holding
Funds holding: 243 → 265 (+22)
1.34% less ownership
Funds ownership: 31.44% → 30.1% (-1.3%)
24% less call options, than puts
Call options by funds: $51M | Put options by funds: $67.2M
25% less funds holding in top 10
Funds holding in top 10: 8 → 6 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$185M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$102M |
| 3 |
Capital International Investors
Los Angeles,
California
|
+$48.9M |
| 4 |
Morgan Stanley
New York
|
+$25.8M |
| 5 |
1832 Asset Management
Toronto,
Ontario, Canada
|
+$24.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$152M |
| 2 |
PBA
Paradigm Biocapital Advisors
New York
|
-$84.2M |
| 3 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
-$73.3M |
| 4 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$56.1M |
| 5 |
Millennium Management
New York
|
-$55.7M |
ONC Hedge Fund Activity: Q3 2025 in Review
265 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in BeOne Medicines Ltd (ONC) for Q3 2025, worth a combined $11.2B — up 35% from $8.34B a quarter earlier.
Buyers outnumbered sellers: 62 funds opened new ONC positions and 40 closed out — a net gain of 22 holders — while 91 added to existing stakes and 78 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $185M. The largest seller was Citadel Advisors, cutting an estimated $152M.
- 265 institutional investors held BeOne Medicines Ltd (ONC) as of Q3 2025, up from 243 in Q2 2025.
- Funds reported $11.2B of BeOne Medicines Ltd stock for Q3 2025, up 35% quarter-over-quarter.
- 62 funds opened new BeOne Medicines Ltd positions in Q3 2025 and 40 closed out, a net change of +22 holders.
- The largest BeOne Medicines Ltd buyer in Q3 2025 was T. Rowe Price Associates, an estimated $185M added.
- The largest BeOne Medicines Ltd seller in Q3 2025 was Citadel Advisors, an estimated $152M sold.
Based on aggregated 13F filings for Q3 2025.